Clinical Trials
361 trialsClinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Chidamide Bridging for CAR-T Therapy
Chinese PLA General Hospital
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
HRYZ Biotech Co.
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Shanxi Province Cancer Hospital
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Shanxi Province Cancer Hospital
CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma
Fudan University
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Henan Cancer Hospital
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Salarius Pharmaceuticals, LLC
CLOVER
Fudan University
Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
Anhui Provincial Hospital
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
VICTORY
Melbourne Health
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Salarius Pharmaceuticals, LLC
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors
European Institute of Oncology
VEX
European Institute of Oncology
Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
Zhejiang Provincial People's Hospital
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Sun Yat-sen University
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.
Shanghai Zhongshan Hospital
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
BGI, China
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Chongqing University Cancer Hospital
FB-12
NSABP Foundation Inc
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Shanghai Ming Ju Biotechnology Co., Ltd.
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Barbara Ann Karmanos Cancer Institute
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
Zhejiang University
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
EBV CAR-T Cells for Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
easy laugh
Shanghai Pudong Hospital
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
Fujian Cancer Hospital
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
Fujian Cancer Hospital
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Henan Cancer Hospital
Reduced Chemotherapy in Low Risk DLBCL
Ruijin Hospital
Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients
Moscow Clinical Scientific Center
T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Karolinska University Hospital
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
PETHEMA Foundation